The burgeoning popularity of semaglutide , initially for diabetes , is creating significant attention within the UK , prompting a notable shift in peptide trends. Availability these treatments remains a complex situation , with NHS provision currently limited and private clinics offering treatment at a substantial price. Worries are being raised re